Keyphrases
Adverse Cardiovascular Events
25%
All-cause Mortality
57%
Aortic Stenosis
100%
Aortic Valve Replacement
28%
Atrial Fibrillation
73%
Cardiovascular Disease
15%
Cardiovascular Events
68%
Cardiovascular Mortality
82%
Cataract
25%
Confidence Interval
46%
Coronary Artery Bypass Grafting
17%
Dilatation
25%
Eccentric Hypertrophy
25%
End-diastolic Volume
25%
Ezetimibe
78%
Group Classification
25%
Hazard Ratio
30%
Heart Rate
27%
Hypertensive Patients
50%
Inflammation
15%
Left Ventricular Hypertrophy
53%
Life Studies
25%
Lipid-lowering
27%
Losartan
42%
Low Risk
35%
LV Mass
20%
Major Adverse Cardiovascular Events
15%
Meta-analysis
25%
Multivariable
15%
Myocardial Infarction
68%
New Biomarkers
25%
New-onset Atrial Fibrillation
88%
Non-associated
25%
Non-fatal
18%
Nonfatal Stroke
18%
Persistent Atrial Fibrillation
25%
Preventive Effect
28%
Propensity Score Analysis
15%
Psoriasis
25%
Reinfarction
18%
Renin-angiotensin System
25%
Renin-angiotensin System Inhibitors
25%
Resting Heart Rate
25%
Severe Aortic Stenosis
42%
Simvastatin
80%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
25%
Statin Therapy
39%
Statins
57%
Sudden Cardiac Death
25%
Systematic Meta-analysis
25%
Medicine and Dentistry
All Cause Mortality
42%
Aortic Stenosis
100%
Aortic Valve Replacement
18%
Apoplexy
52%
Atenolol
22%
Atrial Fibrillation
35%
Biological Marker
25%
C Reactive Protein
15%
Cardiovascular Disease
27%
Cardiovascular Mortality
42%
Cardiovascular System
83%
Cataract
25%
End-Diastolic Volume
25%
Ezetimibe
78%
Hazard Ratio
20%
Left Ventricular Hypertrophy
55%
Losartan
50%
Myocardial Infarction
27%
Proportional Hazards Model
24%
Psoriasis
25%
Renin Angiotensin Aldosterone System
25%
Resting Heart Rate
25%
Simvastatin
78%
Sudden Cardiac Death
25%
Urokinase Receptor
25%
Pharmacology, Toxicology and Pharmaceutical Science
All Cause Mortality
63%
Angiotensin
25%
Aortic Stenosis
50%
Atenolol
23%
Atrial Fibrillation
77%
Cardiovascular Mortality
36%
Cataract
25%
Cerebrovascular Accident
46%
Ezetimibe
28%
Heart Infarction
78%
Heart Left Ventricle Hypertrophy
55%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
44%
Infarction
25%
Losartan
51%
New-Onset Atrial Fibrillation
68%
Psoriasis
25%
Renin
25%
Simvastatin
30%
Statin (Protein)
54%
Sudden Cardiac Death
25%